Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Transcript

Why It Matters

The trial and new reimbursement codes position Capricor to accelerate revenue growth and capture a larger share of the $10‑plus‑billion heart‑failure device market.

Key Takeaways

• Q4 revenue $16M, up 4% YoY
• Gross margin improved to 86% from 83%
• Net loss widened to $11.9M despite revenue growth
• Active implanting centers increased 13% to 252
• BENEFIT HF trial could triple market to $30B

Pulse Analysis

Capricor Therapeutics is leveraging its Barostim neuromodulation platform to address a sizable unmet need in heart‑failure patients who remain symptomatic despite optimal drug therapy. The company’s modest revenue lift in Q4 reflects a broader commercial foundation built in 2025, including a 10% expansion of U.S. sales territories and a 13% increase in active implanting centers. Higher average selling prices and improved manufacturing efficiencies boosted gross margin to 86%, underscoring the scalability of its device production while the firm continues to invest heavily in sales talent and targeted account strategies.

A pivotal development for Capricor is the transition to a Category I CPT code, which standardizes reimbursement and reduces prior‑authorization friction. Coupled with a jump in Medicare Advantage prior‑authorization approval from 31% to 46%, the new coding framework is expected to enhance payer confidence and accelerate patient access. The company’s balance sheet remains robust, with $75.7 million in cash and an amended debt facility extending maturity to 2031, providing a $40 million contingent line tied to performance milestones. These financial safeguards give Capricor the runway to fund growth initiatives while managing operating burn.

The launch of the BENEFIT HF trial marks a strategic inflection point. Enrolling 2,500 patients across the United States and Germany, the study aims to demonstrate mortality and decompensation benefits in a broader heart‑failure cohort, potentially tripling the addressable market from $10.5 billion to $30 billion. CMS Category B IDE coverage ensures Medicare reimbursement for trial procedures, translating to an estimated $20‑30 million cash impact over the next five to seven years. With 2026 revenue guidance of $63‑$67 million and continued expansion of sales territories, Capricor is poised to convert clinical validation into sustained commercial momentum.